Vivera Partners with NINDS of NIH to Identify Potential Stuttering Treatments
Vivera Executes Letter of Intent to Enter a Cooperative Research and Development Agreement with the NINDS of NIH to Assess Therapeutic Agents for Potential Treatments
Vivera Enters $23 Billion Telehealth Industry with Patent Allowance for MDZone
NEWPORT BEACH, Calif. — Vivera Pharmaceuticals, Inc. is pleased to announce that it has received a Notice of Allowance for U.S. Patent Application No. 17/066,985
Will Recent $32 Billion in Opioid Settlements Prevent Addiction? Vivera Has the Answer.
NEWPORT BEACH, Calif.— As large corporations are being held responsible for fueling the opioid crisis, an estimated $32 billion in settlements are being allocated to
Vivera Engages Star Legal Team to Lead $500 Million Lawsuit Against USA Today
NEWPORT BEACH, Calif.— Vivera Pharmaceuticals, Inc. today announced the appointment of leading corporate law firm, Byrd Campbell, P.A., to represent the Company in its defamation
Vivera Pharmaceuticals Issues Statement Regarding LuSys Laboratories Covid-19 Tests
Vivera Pharmaceuticals is highly discouraged to read the latest FDA safety communication that erroneously lists Vivera Pharmaceuticals as a brand of LuSys Laboratories or as
Vivera Appoints Donald D’Ambrosio as Chief Financial Officer
NEWPORT BEACH, Calif. — Vivera Pharmaceuticals announced today, the appointment of Donald D’Ambrosio as the Company’s Chief Financial Officer (CFO). With over four decades of experience serving in executive and
Investor Relations and Media Inquiries:
Investor Inquiries:
[email protected]
Media Inquiries:
[email protected]
Forward-looking and cautionary statements:
Statements made on our website may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Vivera, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Vivera and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Vivera’s future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Vivera’s expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Vivera, reference should be made to Vivera’s continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Vivera’s CSE Listing Statement. The forward-looking information contained on our website is made as of the date of the release of such statement and Vivera does not intend, and expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents on our site.
